Phase I trial of intravenous fenretinide (4-HPR) for patients with hematologic malignancies.

Trial Profile

Phase I trial of intravenous fenretinide (4-HPR) for patients with hematologic malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Fenretinide (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2017 Results assessing PK and efficacy of intravenous fenretinide emulsion, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 25 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top